Bioceltix is getting closer to the registration of BCX‑CM‑J for osteoarthritis in dogs. The dialogue with the European Medicines Agency enters the next phase

Bioceltix has announced that it has submitted responses to the European Medicines Agency (EMA) regarding questions related to the BCX‑CM‑J product. This is one of the key elements of the registration process preceding the marketing authorisation of the drug. BCX‑CM‑J, developed by the Wrocław‑based biotech company, has the potential to become the world’s first veterinary […]